– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. New research suggests that the casirivimab-imdevimab monoclonal antibody treatment for COVID-19 ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

And for patients facing extreme limitations to mobility, or who live vast distances from hospitals and clinics, mobile ...